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Context: Primary adrenal failure is a life-threatening condition that
can be caused by a range of etiologies, including autoimmune, met-
abolic, and developmental disorders. The nuclear receptors DAX1
(NR0B1) and steroidogenic factor-1 (SF1/Ad4BP, NR5A1) play an
important role in adrenal development and function, and mutations
in these transcription factors have been found in patients with ad-
renal hypoplasia.
Objective: Our objective was to investigate the prevalence of DAX1
and SF1 mutations in children and adults with primary adrenal
failure of unknown etiology (i.e. not caused by congenital adrenal
hyperplasia, adrenoleukodystrophy, or autoimmune disease).
Patients: One hundred seventeen patients were included. Eighty-
eight individuals presented in infancy or childhood with adrenal
hypoplasia or primary adrenal failure of unknown etiology (n  64
46,XY phenotypic males; n  17 46,XY gonadal dysgenesis/im-
paired androgenization; n  7 46,XX females). Twenty-nine indi-
viduals presented in adulthood with Addison’s disease of unknown
etiology.
Methods: Mutational analysis of DAX1 (NR0B1) (including exon
2/1A) and SF1 (NR5A1) was done by direct sequencing.
Results: DAX1 mutations were found in 58% (37 of 64) of 46,XY phe-
notypic boys referred with adrenal hypoplasia and in all boys (eight of
eight) with hypogonadotropic hypogonadism and a family history sug-
gestive of adrenal failure in males. SF1 mutations causing adrenal fail-
ure were found in only two patients with 46,XY gonadal dysgenesis. No
DAX1 or SF1 mutations were identified in the adult-onset group.
Conclusions: DAX1 mutations are a relatively frequent cause of
adrenal failure in this group of boys. SF1 mutations causing adrenal
failure in humans are rare and are more likely to be associated with
significant underandrogenization and gonadal dysfunction in 46,XY
individuals. (J Clin Endocrinol Metab 91: 3048–3054, 2006)
PRIMARY ADRENAL FAILURE is a potentially life-threatening disorder that can present with a salt-
losing crisis or profound hypoglycemia in infancy or child-
hood and requires urgent resuscitation and appropriate
steroid replacement. Determining the exact cause of this
condition can be challenging once the child has started
treatment, but defining a precise etiology has important
implications for long-term management, for identifying
associated features, and for appropriate counseling re-
garding inheritance and the risks of other family members
being affected (1, 2).
Two related transcription factors that have emerged as key
regulators of adrenal development are the nuclear receptors
DAX1 [dosage-sensitive sex reversal, adrenal hypoplasia con-
genita (AHC), critical region on the X chromosome, gene-1,
NR0B1/AHC] and steroidogenic factor-1 (SF1, NR5A1, also
known as Ad4BP) (3).
Deletions or mutations of DAX1 (NR0B1, Xp21) [Men-
delian Inheritance in Man (MIM) no. 300473] cause the
X-linked form of primary adrenal hypoplasia (AHC) (MIM
no. 300200) (4, 5). Boys with this condition usually present
with salt-losing primary adrenal failure in early infancy or
in childhood (6). Absent or arrested puberty occurs in
adolescence because of hypogonadotropic hypogonadism
(HH), and intrinsic abnormalities in spermatogenesis con-
tribute to impaired fertility (4–10). Although more than
100 individuals or kindred with X-linked AHC have been
reported, the prevalence of DAX1mutations in individuals
with different adrenal phenotypes or associated features is
not clear (11–18).
Recently, a late-onset form of X-linked AHC has been
described in several individuals who first presented with
adrenal failure and partial hypogonadism in adulthood (19–
21). These reports raise the possibility that milder or even
adrenal-only forms of AHC resulting from DAX1 mutations
could exist. Furthermore, as gonadal (testicular) dysgenesis
has now been reported in Dax1 (Ahch) deleted mice when
bred onto certain genetic backgrounds (22), we hypothesize
that DAX1mutationsmight be identified in a subset of 46,XY
individuals with primary adrenal failure and impaired tes-
ticular development.
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The related nuclear receptor SF1 (NR5A1) (9q33) regulates
transcription ofmany genes involved in adrenal and gonadal
development, steroidogenesis, and reproduction (23, 24).
Targeted deletion of Sf1 in the mouse causes adrenal and
gonadal agenesis, retained Mu¨llerian structures, and im-
paired androgenization in males, abnormal gonadotropin
release, and late-onset obesity (25, 26).
Human mutations in SF1 have been described in three
patients with primary adrenal failure to date (MIM no.
184757). Two individuals with a 46,XY genotype, female
phenotype, and Mu¨llerian structures harbor missense mu-
tations that affect DNA binding (27–29), whereas a 46,XX girl
with a SF1 mutation has primary adrenal failure and appar-
ently normal ovarian development (30). In addition, it is now
emerging that heterozygous nonsense or frameshift muta-
tions associated with haploinsufficiency of SF1 can cause
46,XY gonadal dysgenesis in patients with normal adrenal
function (31–33). Thus, it is possible that a range of different
endocrine phenotypes could be associated with mutations in
different domains of SF1.
Here, we report our experience over the past 10 yr of
analyzing DAX1 and SF1 in 117 children and adults with
primary adrenal failure that is not caused by disorders that
are commonly recognized (i.e. congenital adrenal hyperpla-
sia, adrenoleukodystrophy, or autoimmune disease).
Subjects and Methods
Subjects
A total of 117 individuals with primary adrenal failure were consid-
ered for this study (Table 1). This cohort represents referrals to our
centers over a 10-yr period. For the purposes of this analysis, we have
included 15 mutations identified and reported in the literature by our
groups (6–8, 27, 28, 34–36). We have omitted cases where a molecular
diagnosis had been made elsewhere and we undertook functional work
(e.g. 19–21). Thus, our aim was to obtain an estimate of the relative
prevalence of DAX1 and SF1 mutations in individuals with adrenal
insufficiency that was not readily attributed to disorders that are com-
monly diagnosed in practice, such as autoimmune conditions or classic
steroidogenic defects.
Subjects were divided into infancy/childhood-onset and adult-onset
groups (infancy, 1 yr; childhood, 1–15 yr; adult, 15 yr). Steroid
biosynthetic defects (e.g. 21-hydroxylase deficiency), metabolic disor-
ders (e.g. adrenoleukodystrophy), and autoimmune disorders (e.g. au-
toimmune Addison’s disease, polyglandular autoimmune endocrinop-
athy) had been excluded, where relevant. No patients had features of a
syndrome causing adrenal insufficiency where the genetic etiology is
known (e.g. triple A syndrome, AAAS).
The infancy/childhood-onset group consisted of 88 individuals who
presentedwith salt-losing adrenal failure early in life.Most of this group
were 46,XY phenotypic males (n 64), with or without a family history
of primary adrenal failure and/or unexplained death in infancy/child-
hood or a personal history of abnormal puberty/HH (Tables 1 and 2).
Other clinical features (e.g. skeletal abnormalities or intrauterine growth
retardation) were present in 12 patients. Of these, six individuals had
potential variants on the IMAGe syndrome (intrauterine growth retar-
dation, metaphyseal dysplasia, adrenal hypoplasia, genitourinary ab-
normalities), but no children had features of the Antley-Bixler syndrome
(37). Transient or borderline adrenal failure was present in five cases
(Table 2). This phenomenon was defined as a cortisol response to syn-
acthen less than 15 g/dl (420 nmol/liter) when investigated for hy-
poglycemia in the neonatal period and requiring steroid replacement for
several months or years, which was eventually weaned and stopped
(Table 2). These boys were included because transient forms of AHC
have been described in patients who present in early infancy, improve
in childhood, but develop significant adrenal failure in adolescence (38).
In addition to the 46,XY phenotypic males, we considered a cohort of
underandrogenized 46,XY patients (ambiguous genitalia or female phe-
notype) with primary adrenal failure (n  17), with (n  4) or without
(n 13)Mu¨llerian structures, aswell as a small group of 46,XX girls with
isolated primary adrenal failure of unknown etiology (n  7) (Table 1).
Three of the underandrogenized 46,XY children had low birth weight or
mild dysmorphic features. Two of these 46,XX girls had evidence of low
birth weight and short stature/skeletal abnormalities.
The adult-onset group (n 29) consisted of 46,XYmales (n 14) and
46,XX females (n  15) who presented with primary adrenal failure of
unknown etiology after puberty (median age, 33 yr; range, 15–70 yr)
(Table 1). These patients were thought initially to have autoimmune
Addison’s disease but were autoantibody negative and had no other
autoimmune endocrinopathies or infective causes and no remarkable
family history. Onemale had partial HH, and all patients were receiving
mineralocorticoid replacement.
Mutational analysis of DAX1 (NR0B1) and SF1 (NR5A1)
After institutional board approval and with informed consent,
genomic DNA was extracted from peripheral blood lymphocytes and
the entire coding regions and splice sites of SF1 (NR5A1, exons 2–7, 10
primer pairs) and DAX1 (NR0B1, exons 1–2, six primer pairs) were
amplified by PCR using variations on conditions reported previously.
Exon 2/1A of DAX1/NR0B1A was amplified by the following prim-
ers: forward, 5-CTCTGTGATGATTGGCATGGTG-3; reverse, 5-
GCAGTATAGTGTGATACCGAAG-3 (39, 40). PCR products were pu-
rified by gel extraction (QIAGEN, Valencia, CA) or by using exonuclease
I (New England Biolabs, Ipswich, MA)/shrimp alkaline phosphatase
(USB, Columbus, OH) and then subjected to direct sequencing using dye
terminator sequencing kits (dRhodamine/BigDyev1.1 from PE Applied
Biosystems Inc., Foster City, CA) and automated gel or capillary-based
sequencers (373A/377 from PE Applied Biosystems; MegaBACE1000
from Amersham Biosciences Inc., Piscataway, NJ). Sequence Navigator
(PE Applied Biosystems), Sequence Analyser version 3.0 (Amersham
Biosciences), and Sequencher version 4.1 (Genecodes Corp., Ann Arbor,
MI) were used to analyze the data.
Results
Analysis of DAX1
Mutation analysis revealed a total of 37 DAX1 mutations
in the cohort studied. All of these changes were identified in
TABLE 1. Mutational analysis of DAX1 (NR0B1) and SF1 (NR5A1) in children referred with potential adrenal hypoplasia and in adults
with Addison’s disease of unknown etiology
Infancy/childhood onset (n  88) Adult onset (n  29)
46,XY male
46,XY underandrogenized
46,XX female 46,XY male 46,XX female
No Müllerian structures Müllerian structures
No. of patients 64 13 4 7 14 15
Median age (range) 10 d (birth to 13 yr) 7 d (birth to 2.5 yr) 10 d (birth to 3 wk) 2 yr (6 d to 6 yr) 29 yr (15–67 yr) 38 yr (28–70 yr)
Mutations
DAX1 37 0 0 0 0 0
SF1 0 0 2 0 0 0
Age refers to median age (range) at presentation.
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46,XY phenotypic males who had presented with primary
adrenal failure in infancy or childhood (37 of 64, 58%) (Table
1). No DAX1 mutations were found in the underandrog-
enized 46,XY subjects, in 46,XX girls with adrenal failure, or
in any of the adult-onset group. No mutations were identi-
fied in exon 2/1A of DAX1/NR0B1.
Most boys with DAX1 mutations presented in early in-
fancy compared with childhood (30 of 37, 81%). A typical
bimodal distribution pattern of ages was observed (early
infancy n  30, 5–60 d; childhood n  7, 2–13 yr) (6). Al-
though age at presentation was similar in the group where
no DAX1mutations were found (21 of 27, 78%, presenting in
infancy) (Table 2), boys who were found to harbor a DAX1
mutation were more likely to have a positive family history
of adrenal failure or unexplaineddeath inmales or a personal
history of abnormal puberty/HH (Table 2). Indeed, all (eight
of eight, 100%) individuals with a positive family history and
abnormal puberty had a DAX1 mutation.
Despite the importance of family history and HH as po-
tential indicators of X-linked AHC, the prevalence of DAX1
mutations was still 45% (20 of 44) in boys with no family
history who were preadolescent (14 yr) at the time of re-
ferral. Furthermore, milder or transient forms of adrenal
insufficiency or associated features such as skeletal abnor-
malities were more likely to be found in the group in whom
no DAX1 mutations were identified (Table 2). If these indi-
viduals with transient adrenal insufficiency or additional
features were excluded from analysis, the percentage of pre-
adolescent boys with no family history who were found to
harbor DAX1 mutations rose from 45% (20 of 44) to 68% (19
of 28).
The proportions of different DAX1 mutations identified
compared with those reported in the literature are shown in
Fig. 1. Deletion of the locus containing DAX1/NR0B1 (Xp21)
was found in 10 patients (27%). Eight of these deletions
involved only the NR0B1 gene, whereas two patients had a
contiguous gene deletion syndrome including glycerol ki-
nase deficiency (GKD) and Duchenne muscular dystrophy
(DMD). In both of these cases, the molecular diagnosis was
made in the first months of life before the onset of neuro-
muscular or developmental symptoms/signs. The remain-
der (n  27) of DAX1 mutations were nonsense (n  7),
TABLE 2. Characteristics of boys (46,XY) with and without DAX1 mutations/deletions
Total cohort
(46,XY boys)
DAX1 mutation detected
n (%)
No mutation detected
n (%)
Total no. 64 37 (58) 27 (42)
Age at presentation
Early infancy 51 30 (59) 21 (41)
Childhood 13 7 (54) 6 (46)
Puberty/FH
Prepubertal/no FH 44 20 (45) 24 (55)
Prepubertal/FH 9 6 (67) 3 (33)
HH/no FH 3 3 (100) 0 (0)
HH/FH 8 8 (100) 0 (0)
Additional features 12 1 (8) 11 (92)
Transient/mild adrenal dysfunction 5 0 (0) 5 (100)
The data are focused on age at presentation, presence or absence of HH and/or family history (FH) of adrenal failure or unexplained death,
presence of additional clinical features (e.g. skeletal abnormalities and intrauterine growth retardation), and severity of adrenal dysfunction.
FIG. 1. Relative prevalence of different
types of DAX1 mutations in this series
(A) compared with the published litera-
ture (excluding abstracts) (B). Data
shown represent the total number of dif-
ferent individuals or kindred with muta-
tions. The historical literature has a bias
toward cases of contiguous gene deletion
syndrome where X-linked AHC has been
reported together with glycerol kinase
deficiency, Duchenne muscular dystro-
phy, and/or X-linked mental retardation.
Our series focused on children with pri-
mary adrenal failure. In the two cases of
contiguous gene deletion found, the di-
agnosis of a deletion of the DAX1 (AHC)
locus was made before the clinical or bio-
chemical diagnosis of glycerol kinase de-
ficiency/Duchenne muscular dystrophy.
3050 J Clin Endocrinol Metab, August 2006, 91(8):3048–3054 Lin et al. • DAX1 and SF1 in Adrenal Failure
frameshift (n  12), or missense changes (n  8). These
nonsense and frameshift changes are located throughout the
NR0B1 gene with a similar distribution to previous reports
(Fig. 2A). Missense mutations, once thought to be relatively
rare, were found in 22% of cases and involved highly con-
served amino acids in the putative ligand-binding domain of
DAX1 (Fig. 2B).
Analysis of SF1
Mutational analysis of SF1 in this cohort of individuals
with primary adrenal failure revealed mutations in two pa-
tients (Table 1) (Fig. 3). These cases have been reported pre-
viously (27, 28). Both these individuals were found to have
a 46,XY genotype, female phenotype, and Mu¨llerian struc-
tures in addition to adrenal failure and harbored missense
mutations that affected DNA binding (de novo heterozygous
G35E; recessively inherited homozygous R92Q). No SF1 mu-
tations were identified in 46,XY males with adrenal hyp-
oplasia, in underandrogenized 46,XY females without Mu¨l-
lerian structures, in 46,XX girls, or in the adult-onset adrenal
failure group.
Discussion
The past 15 yr have seen significant progress in our un-
derstanding of the molecular basis of childhood adrenal dis-
orders. More than 20 single-gene disorders have now been
reported that can affect adrenal function in infancy or child-
hood, and a genetic diagnosis should be attainable in well
over 50% of individuals with these conditions (2). Obtaining
a precise biochemical and genetic diagnosis can have im-
portant consequences for treatment, for predicting progno-
sis, for investigating possible associated features, and for
counseling the individual and family so that the risk of other
family members being affected can be assessed accurately.
The identification and characterization of DAX1 as the
cause of X-linked primary AHC in 1994 has had significant
implications for diagnosis of individuals and families with
this condition. An association with disordered puberty
means that themajority of boyswith X-linkedAHCwill need
pubertal induction and long-term sex steroid replacement. It
also seems likely that an intrinsic defect in spermatogenesis,
which may be present in humans as well as mice, results in
a worse fertility prognosis for individuals with X-linked
AHC compared with young men with isolated idiopathic
HH (8, 19, 20).
The true population prevalence of DAX1 mutations is not
currently known. The prevalence of congenital adrenal hy-
poplasia is often quoted as being 1:12,500, following the 13-yr
study of infant autopsies at the Royal Women’s Hospital,
Melbourne, Australia (1959–1971) by Laverty et al. (41).
However, there was no sex bias in cases (six of 11 male), and
only one male infant had cytomegalic histological changes
consistent with the X-linked form of AHC. Furthermore, in
a 20-yr review of primary adrenal insufficiency in children
(0–18 yr) presenting to Sainte-Justine Hospital, Montreal
(1981–2001), and reported by Perry et al. (42), X-linked AHC
resulting from a DAX1 mutation was found in only one boy
(one of 103). Congenital adrenal hyperplasia was diagnosed
in 74 of 103 children (71.8% of the population) and has an
estimated occurrence of 1:16,630 (42). Taken together, these
studies suggest that X-linked AHCmight occur in anywhere
between 1:140,000 and 1:1,200,000 children (or between
1:70,000 and 1:600,000 males). However, extreme caution is
needed in interpreting these data, as the number of boyswith
X-linked AHC in each cohort was extremely small (n  1).
Here, we have focused on children and adults with pri-
mary adrenal insufficiency of unknown etiology,where com-
mon causes of adrenal failure such as steroidogenic defects
(e.g. 21-hydroxylase deficiency) andmetabolic disorders (e.g.
X-linked adrenoleukodystrophy) had been excluded. We
FIG. 2. A, Overview of nonsense (black) and frameshift (red) muta-
tions in DAX1. Specific mutations identified by our centers are shown
below the DAX1 model. Previously reported changes in the literature
are shown above the DAX1 model by arrowheads. B, Naturally oc-
curring missense mutations in DAX1 cluster within the carboxy ter-
minus of DAX1 in a region that is homologous to the ligand-binding
domain (LBD) of nuclear receptors. Mutations identified by our cen-
ters are shown in red, whereas mutations reported in the literature
are shown in black. The three major cluster regions are indicated by
black bars. Single amino acid deletions (d269V, d430N) are included.
FIG. 3. Mutations in SF1 (Ad4BP) associated with primary adrenal
failure and 46,XY gonadal dysgenesis affect the P-box and A-box
regions of the DNA-binding domain (G35E, R92Q). A heterozygous
mutation has also been reported in a 46,XX girl with primary adrenal
failure and apparently normal ovarian differentiation (R255L) (30).
LBD, Ligand-binding domain.
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show that DAX1 mutations are a relatively frequent cause of
adrenal failure in phenotypic boys (46,XY) referred to uswith
potential primary adrenal hypoplasia. DAX1mutationswere
found in over half of individuals studied (37 of 64, 58%), and
in all eight (100%) cases where there was a family history of
adrenal failure or unexpected death inmales (consistentwith
an X-linked inheritance pattern) together with a history of
arrested or absent puberty. Thus, detailed questioning about
family history that could reveal any insight into possible
adrenal disease is important. Furthermore, when no such
family history was obtained, and when the individual was
prepubertal at the time of assessment, it was still possible to
detect DAX1 mutations in a substantial proportion of cases
(20 of 44, 45%). If boys with additional features (e.g. low birth
weight or skeletal abnormalities) and those with transient
forms of adrenal failure were omitted from analysis, the
proportion of boyswithDAX1 changes found rose to 68% (19
of 28). Thus, mutational analysis of DAX1 may be worth-
while in any male infant presenting with salt-losing adrenal
failure, where steroidogenic disorders (e.g. 21-hydroxylase
deficiency, P450 oxidoreductase deficiency), metabolic con-
ditions (e.g. Wolman syndrome and Zellweger syndrome),
multisystem syndromes (e.g. IMAGe), and adrenal hemor-
rhage have been excluded, and in the older child where, in
addition, autoimmune endocrine disorders (e.g. autoim-
mune polyendocrinopathy-candidiasis-ectodermal dystro-
phy syndrome, autoimmune polyglandular syndrome 2, and
isolated autoimmune Addison’s disease), syndromic ACTH
resistance syndromes (e.g. triple A), infection, or iatrogenic
causes of adrenal failure are not present.
The 37 DAX1 mutations and deletions detected had a
similar distribution to those reported in the literature to date,
although we did identify relatively few contiguous gene
deletion syndromes compared with isolated deletions of
NR0B1 and a significant proportion of missense mutations
(Fig. 1) (3, 43). The contiguous gene deletion syndromeswere
diagnosed before the onset of signs and symptoms of mus-
cular dystrophy in both the cases shown. Although none of
our cohort has evidence of deletion of the IL1RAPL1 gene
telomeric toNR0B1, which is associated with developmental
delay, it is important to be aware of this potential association
when a childwith a Xp21 deletion seems to be failing to reach
developmental milestones (44). The nonsense and frameshift
mutations in our cohort were located throughout the NR0B1
gene, with relatively few hotspots that could help to focus
sequencing strategies. Missense mutations in DAX1 do tend
to cluster in certain regions of the ligand-like binding do-
main, in highly conserved amino acids (35).
No SF1 mutations were found in the cohort of boys (n 
27) who did not have abnormalities in DAX1. These findings
suggest that mutations in SF1 are unlikely to be a frequent
cause of an adrenal-only phenotype, with normal male sex
development. Other candidate genes for this group include
potential regulators of adrenal development that are emerg-
ing from studies of gene expression or transgenic mice (e.g.
ACD, CITED2, and PBX1). Several of our patients had phe-
notypic features consistent with a variant of the IMAGe
syndrome, but the molecular basis of this condition is at
present unknown (37, 45, 46). None of these children were
found to harbor changes in DAX1 or SF1.
Analysis of our cohort of 46,XY individuals with adrenal
failure and gonadal dysgenesis/impaired androgenization
failed to reveal any DAX1 mutations, although there is ev-
idence from studies of transgenic mice that Dax1 may func-
tion to support testis development at early stages of embry-
ogenesis (9, 22, 47). SF1 mutations were found in only two
patients, both of whom had 46,XY complete gonadal dys-
genesis and persistent Mu¨llerian structures (27, 28). These
findings are consistent with the hypothesis that gene dosage
effects of SF1 are important and that gonadal (testicular)
development is more sensitive to loss of SF1 function than
adrenal development in humans (48). Thus, if severe adrenal
failure is present because of an SF1 mutation, it is likely that
there will be significant underandrogenization, whereas less
severe disruption of SF1 can result in partial gonadal dys-
genesis/impaired androgenization, and normal adrenal
function (31–33). It is possible that mutations in the SF1
promoter or noncoding sequences, or in related target genes
or cofactors, might be identified in those individuals where
no SF1mutations were found. Furthermore, abnormalities in
the early stages of steroidogenesis (e.g. steroidogenic acute
regulatory protein, CYP11A) might present as complete ad-
renal failure and impaired androgenization, but without
Mu¨llerian structures. The adrenal glands in children with
these conditions may not always be enlarged.
Our reports of a late-onset form of X-linked AHC pre-
senting with primary adrenal failure in young adulthood in
three men (19–21) as well as potential female phenotypic
expression of DAX1-related phenotypes (8) led to studies of
DAX1 and SF1 in a cohort of 29 men and women who had
Addison’s disease of unknown etiology. Thus, we hypoth-
esized that milder forms of AHC might account for a subset
of patients with these phenotypes. However, no mutations
were found. Although the number of patients was small,
these findings suggest that mild forms of adrenal hypoplasia
are unlikely to be found in patients with adult-onset Addi-
son’s disease of unknown etiology in the absence of at least
partial HH in males (DAX1) or impaired androgenization
(SF1).
Taken together, this study shows that mutations in DAX1
are a relatively frequent cause of primary adrenal hypopla-
sia, even in the absence of a positive family history of adrenal
failure or unexpected death in males or a personal history of
abnormal puberty. In contrast, although SF1 mutations are
emerging as a cause of 46,XY gonadal dysgenesis in patients
with normal adrenal function, SF1mutations causing adrenal
failure are rare and are likely to be associatedwith significant
underandrogenization and gonadal dysfunction in 46,XY in-
dividuals. Genetic analysis of DAX1 is now offered by a
number of clinical laboratoriesworldwide. The prevalence of
DAX1 changes identified in our series might warrant having
a low threshold to undertake this analysis. Although pur-
suing a commercial approach can be relatively expensive, it
may well be worthwhile if such an approach was able to
prevent recurrent hypoglycemia, a severe salt-losing crisis,
or even death in a presymptomatic brother or male relative
or after a future pregnancy (34). However, it is also important
that appropriate counseling is available for the individual
and family throughout their interactions with health care
services over the years, that appropriate and timely trans-
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lation of care from pediatric to adult services is established,
and that the clinical and research communitieswork together
to determine the molecular basis of disorders of adrenal
development when no changes in DAX1, SF1, or other can-
didate genes are found.
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